These findings suggest that PARP-1, as well as parthanatos process, plays a multifaceted role in gastric cancer, influencing tumorigenesis, chemotherapy resistance, and therapeutic response, making it a potential biomarker and therapeutic target for improving treatment outcomes. The gene discussed is PARP1; the disease is gastric cancer.